International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Alison H. Kohn; Afsaneh Alavi; April W. Armstrong; Folawiyo Babalola; Amit Garg; Alice B. Gottlieb; Lesley Grilli; Gregor Borut Ernst Jemec; John Latella; Kendall Marcus; Joseph F. Merola; Alex G. Ortega-Loayza; Daniel M. Siegel; Vibeke Strand; Jerry K.L. Tan; Lourdes M. Perez-Chada

doi:10.1159/000518966

International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Alison H. Kohn, Afsaneh Alavi, April W. Armstrong, Folawiyo Babalola, Amit Garg, Alice B. Gottlieb, Lesley Grilli, Gregor Borut Ernst Jemec, John Latella, Kendall Marcus, Joseph F. Merola, Alex G. Ortega-Loayza, Daniel M. Siegel, Vibeke Strand, Jerry K.L. Tan, Lourdes M. Perez-Chada

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

Original language	English (US)
Pages (from-to)	430-437
Number of pages	8
Journal	Dermatology
Volume	238
Issue number	3
DOIs	https://doi.org/10.1159/000518966
State	Published - May 1 2022

Keywords

Acne
Actinic keratosis
Hidradenitis suppurativa
IDEOM
Patient-Reported Outcome Measures
Psoriasis
Psoriatic arthritis
Pyoderma gangrenosum

ASJC Scopus subject areas

Dermatology

Access to Document

10.1159/000518966

Cite this

Kohn, A. H., Alavi, A., Armstrong, A. W., Babalola, F., Garg, A., Gottlieb, A. B., Grilli, L., Jemec, G. B. E., Latella, J., Marcus, K., Merola, J. F., Ortega-Loayza, A. G., Siegel, D. M., Strand, V., Tan, J. K. L., & Perez-Chada, L. M. (2022). International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 238(3), 430-437. https://doi.org/10.1159/000518966

Kohn, AH, Alavi, A, Armstrong, AW, Babalola, F, Garg, A, Gottlieb, AB, Grilli, L, Jemec, GBE, Latella, J, Marcus, K, Merola, JF, Ortega-Loayza, AG, Siegel, DM, Strand, V, Tan, JKL & Perez-Chada, LM 2022, 'International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting', Dermatology, vol. 238, no. 3, pp. 430-437. https://doi.org/10.1159/000518966

@article{c2689d3a563541959d571e5fff6ca7a3,

title = "International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting",

abstract = "Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.",

keywords = "Acne, Actinic keratosis, Hidradenitis suppurativa, IDEOM, Patient-Reported Outcome Measures, Psoriasis, Psoriatic arthritis, Pyoderma gangrenosum",

author = "Kohn, {Alison H.} and Afsaneh Alavi and Armstrong, {April W.} and Folawiyo Babalola and Amit Garg and Gottlieb, {Alice B.} and Lesley Grilli and Jemec, {Gregor Borut Ernst} and John Latella and Kendall Marcus and Merola, {Joseph F.} and Ortega-Loayza, {Alex G.} and Siegel, {Daniel M.} and Vibeke Strand and Tan, {Jerry K.L.} and Perez-Chada, {Lourdes M.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by S. Karger AG, Basel.",

year = "2022",

month = may,

day = "1",

doi = "10.1159/000518966",

language = "English (US)",

volume = "238",

pages = "430--437",

journal = "Dermatology",

issn = "1018-8665",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - International Dermatology Outcome Measures (IDEOM)

T2 - Report from the 2020 Annual Meeting

AU - Kohn, Alison H.

AU - Alavi, Afsaneh

AU - Armstrong, April W.

AU - Babalola, Folawiyo

AU - Garg, Amit

AU - Gottlieb, Alice B.

AU - Grilli, Lesley

AU - Jemec, Gregor Borut Ernst

AU - Latella, John

AU - Marcus, Kendall

AU - Merola, Joseph F.

AU - Ortega-Loayza, Alex G.

AU - Siegel, Daniel M.

AU - Strand, Vibeke

AU - Tan, Jerry K.L.

AU - Perez-Chada, Lourdes M.

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

AB - Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

KW - Acne

KW - Actinic keratosis

KW - Hidradenitis suppurativa

KW - IDEOM

KW - Patient-Reported Outcome Measures

KW - Psoriasis

KW - Psoriatic arthritis

KW - Pyoderma gangrenosum

UR - http://www.scopus.com/inward/record.url?scp=85115977492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115977492&partnerID=8YFLogxK

U2 - 10.1159/000518966

DO - 10.1159/000518966

M3 - Review article

C2 - 34537770

AN - SCOPUS:85115977492

SN - 1018-8665

VL - 238

SP - 430

EP - 437

JO - Dermatology

JF - Dermatology

IS - 3

ER -

International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this